All posts by: Michael Zand

About Michael Zand

Cancer in the Crosshairs: IMV Looks to Deliver Immunotherapy a New Way – Streetwise Reports

Continue reading

2018-05-16 NEWS

Streetwise Reports

Cancer in the Crosshairs: IMV Looks to Deliver Immunotherapy a New Way
Streetwise Reports
In this interview with The Life Sciences Report, IMV Inc.’s CEO Fred Ors and Pierre Labbè, chief financial officer, describe the innovative immunotherapy platform technology that has attracted partnerships with big pharma, prompted reorganization of

Continue reading

2018-05-16 NEWS

Rare Disease Report

FDA Accepts IND Application for BIVV003, a Gene Therapy for Sickle Cell Disease
Rare Disease Report
This morning, Bioverativ Inc, announced that the US Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for BIVV003, a gene-edited cell therapy candidate for the treatment of people with sickle cell …
FDA Accepts IND for Gene-Edited Cell Therapy BIVV003 for Treatment of Sickle Cell DiseaseMD Magazine

all 2 news articles »

Continue reading

2018-05-16 NEWS

Rare Disease Report

FDA Accepts IND Application for BIVV003, a Gene Therapy for Sickle Cell Disease
Rare Disease Report
This morning, Bioverativ Inc, announced that the US Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for BIVV003, a gene-edited cell therapy candidate for the treatment of people with sickle cell …
FDA Accepts IND for Gene-Edited Cell Therapy BIVV003 for Treatment of Sickle Cell DiseaseMD Magazine

all 2 news articles »